Telo Genomics Corp
XTSX:TELO
Telo Genomics Corp
Telo Genomics Corp. is a biotech company that is developing the most comprehensive telomere analysis platform in the industry, with powerful diagnostic and prognostic applications. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for numerous diseases that display genomic instability. Its lead application, Telo-MM is being developed to provide information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. The firm's TeloView software consists of two parts, analytical software and a corresponding report designed for clinical decision making. TeloView utilizes the three-dimensional analysis of approximately six parameters generated from the telomeres of a single cell. Its TeloView software generates a report for the clinician that contains information, including the stage of a given disease, its rate of progression and how it responds to therapy. Its solutions include liquid biopsies and related technologies in oncology and neurological diseases.
Telo Genomics Corp. is a biotech company that is developing the most comprehensive telomere analysis platform in the industry, with powerful diagnostic and prognostic applications. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for numerous diseases that display genomic instability. Its lead application, Telo-MM is being developed to provide information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. The firm's TeloView software consists of two parts, analytical software and a corresponding report designed for clinical decision making. TeloView utilizes the three-dimensional analysis of approximately six parameters generated from the telomeres of a single cell. Its TeloView software generates a report for the clinician that contains information, including the stage of a given disease, its rate of progression and how it responds to therapy. Its solutions include liquid biopsies and related technologies in oncology and neurological diseases.
